← Back to feed

Futura Medical

FUM · AIM · Health Care · mcap £3.3m today

All announcements

All RNS · 72 Key events · 23

29 Sep 26

Director/PDMR Shareholding Director buys

Futura Medical (AIM:FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that pursuant to the completion of the recent...
RNS 9795261 ↗
24 Sep 26

Result of GM and Total Voting Rights

The following amendment has been made to the 'Result of General Meeting and Total Voting Rights' announcement released on 24/09/26 at 10:36 under RNS No 1721.
RNS 9789690 ↗
10 Sep 26

Directorate Change

Futura Medical plc (AIM: FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that Roy Davis has informed the Company of...
RNS 9764356 ↗
07 Sep 26

Oversubscribed Retail Offer

Unless otherwise defined, definitions contained in this announcement have the same meanings as set out in the Company's announcements dated 3 September 2026.
RNS 9757607 ↗
03 Sep 26

Disclosure Table

The following are today's changes to the Disclosure Table:
RNS 9753689 ↗
03 Sep 26

Retail Offer via the BookBuild Platform Strategic review

The Company is pleased to announce a retail offer via BookBuild to existing shareholders (the "Retail Offer") of up to 75,000,000 new ordinary shares of 0.2 pence each ("Ordinary Shares") in the capital of the Company (the "Retail Offer Shares") at an...
RNS 9753145 ↗
03 Sep 26

Fundraise and launch of FSP and M&A process Strategic review

IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF THE FIRM PLACING AND THE CONDITIONAL PLACING WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN UK MAR), AS PERMITTED BY UK MAR.
RNS 9752865 ↗
01 Sep 26

Unaudited Interim Results 2026 Net cash ≈ market cap

Unaudited interim results for the six months ended 30 June 2026
RNS 9747167 ↗
31 Jul 26

EU Market Launch Clearance

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative, clinically proven sexual health products, is pleased to announce that its new Eroxon® formulation,...
RNS 9697119 ↗
07 Jul 26

MED3000 (Eroxon®) European Patent Opposition

Futura Medical announces that the European Patent Office ("EPO") Opposition Division has issued its written decision confirming the revocation of European Patent No.
RNS 9656950 ↗
30 Jun 26

Highly positive data from WSD4000 studies

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to report the results from two studies on...
RNS 9643048 ↗
29 Jun 26

New US commercial partner

Agreement with Market Performance Group - a leading omnichannel commerce agency
RNS 9640583 ↗
29 Apr 26

Unaudited Results for the Year Ended 31 Dec 2025 Strategic review

Unaudited Results for the Year Ended 31 December 2025
RNS 9542910 ↗
23 Mar 26

Positive Eroxon® & Eroxon® “Intense” HUT results

Positive results from Eroxon® & new Eroxon® "Intense" Home User Test
RNS 9485824 ↗
18 Mar 26

Formal Grant of US Patent

Further to its announcement on 5 February 2026, Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is...
RNS 9479285 ↗
05 Feb 26

Patent notice of allowance granted for the US

Patent notice of allowance granted for MED3000 (Eroxon) in the US
RNS 9410116 ↗
04 Feb 26

Trading Update Strategic review

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to provide an unaudited trading update for...
RNS 9406816 ↗
12 Jan 26

Results of WSD4000 Early Feasibility Study

Highly statistically significant improvement achieved in female sexual function
RNS 9346469 ↗
10 Dec 25

Patent notice of allowance granted for China

Patent notice of allowance granted for MED3000 (Eroxon) in China
RNS 9286610 ↗
08 Dec 25

Director/PDMR Shareholding Director buys

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, confirms that the following Directors and persons...
RNS 9282685 ↗
03 Dec 25

Directorate Change Strategic review

Harmesh was appointed to the Board as Lombard Odier Asset Management's representative in March 2025.
RNS 9271825 ↗
14 Nov 25

PCA Dealing

Futura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that Lombard Odier Asset Management (Europe)...
RNS 9235080 ↗
13 Nov 25

Fundraise of £2.75 million Strategic review

IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF THE PLACING WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN UK MAR), AS PERMITTED BY UK MAR.
RNS 9230247 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.